Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Packer

Showing results (81-90 of 4,796) with videos related to

Pageof 480
Sort By:
Journal of Cardiac Failure|January 7, 2018
Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?Milton Packer
Annals of Internal Medicine|July 1, 1988
Clinical trials in congestive heart failure: why do studies report conflicting results?M Packer
Clinical Ophthalmology (Auckland, N.Z.)|December 13, 2022
The EVO ICL for Moderate Myopia: Results from the US FDA Clinical TrialMark Packer
Journal of the American Heart Association|April 4, 2020
Characterization, Pathogenesis, and Clinical Implications of Inflammation-Related Atrial Myopathy as an Important Cause of Atrial FibrillationMilton Packer
JACC. Heart Failure|July 30, 2021
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in DiabetesMilton Packer
Ophthalmology|December 1, 1987
Iodine-125 radiation of posterior uveal melanomaS Packer
The American Journal of Cardiology|January 25, 1985
Therapeutic application of calcium-channel antagonists for pulmonary hypertensionM Packer
The American Journal of Medicine|September 15, 2019
Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in PsoriasisMilton Packer
JAMA Cardiology|March 23, 2017
Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan-ReplyMilton Packer
Cardiovascular Diabetology|October 6, 2019
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completionMilton Packer
Pageof 480

Showing results (81-90 of 4,796) with videos related to

Sort By:
Pageof 480
Journal of Cardiac Failure|January 7, 2018
Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?Milton Packer
Annals of Internal Medicine|July 1, 1988
Clinical trials in congestive heart failure: why do studies report conflicting results?M Packer
Clinical Ophthalmology (Auckland, N.Z.)|December 13, 2022
The EVO ICL for Moderate Myopia: Results from the US FDA Clinical TrialMark Packer
Journal of the American Heart Association|April 4, 2020
Characterization, Pathogenesis, and Clinical Implications of Inflammation-Related Atrial Myopathy as an Important Cause of Atrial FibrillationMilton Packer
JACC. Heart Failure|July 30, 2021
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in DiabetesMilton Packer
Ophthalmology|December 1, 1987
Iodine-125 radiation of posterior uveal melanomaS Packer
The American Journal of Cardiology|January 25, 1985
Therapeutic application of calcium-channel antagonists for pulmonary hypertensionM Packer
The American Journal of Medicine|September 15, 2019
Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in PsoriasisMilton Packer
JAMA Cardiology|March 23, 2017
Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan-ReplyMilton Packer
Cardiovascular Diabetology|October 6, 2019
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completionMilton Packer
Pageof 480